Skip to main content
Clinical Trials/NL-OMON48499
NL-OMON48499
Completed
Not Applicable

Handheld Laser Speckle Contrast Imaging Device for optical microcirculatory perfusion imaging: Clinical, therapeutic and pathophysiological implications for adult- and paediatric psoriasis. - Handheld Laser Speckle Contrast Imaging in psoriasis.

Radboud Universitair Medisch Centrum0 sites19 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Psoriasis
Sponsor
Radboud Universitair Medisch Centrum
Enrollment
19
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Cohort 1 (8 patients):
  • To enter into this study patients must meet the following criteria:
  • \* \* 18 years of age.
  • \* Patients with a diagnosis of unstable plaque psoriasis according to a dermatologist.
  • \* Patients on topical treatment, who are not eligible or willing to receive systemic anti\-psoriatic treatment.
  • \* Patients must be willing to discontinue their topical treatment on one body area for a maximum of eight weeks.
  • \* Patients must be willing to give a written informed consent.
  • \* Patients must be able to adhere to the visit schedule.;Cohort 2 (8 patients):
  • To enter into this study patients must meet the following criteria:
  • \* \* 18 years of age.

Exclusion Criteria

  • \* Patients with stable plaque psoriasis according to a dermatologist.
  • \* Patients with a history or signs of other inflammatory skin diseases, for example atopic dermatitis.
  • \* Patients on systemic anti\-psoriatic treatment.
  • \* Patients unwilling or unable to give informed consent.;Cohort 2:
  • Patients will be excluded from this study when any of the following criteria listed below are met:
  • \* Patients with a history or signs of other inflammatory skin diseases, for example atopic dermatitis.
  • \* Patients on systemic anti\-psoriatic treatment.
  • \* Patients with a known Koebner phenomenon.
  • \* Patients unwilling or unable to give informed consent.;Cohort 3:
  • \* aged \<6 or \*18 years of age.

Outcomes

Primary Outcomes

Not specified

Similar Trials